The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other Hemoglobinopathies.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical and clinical literature without systematic methodology
PubMed 37759601 · doi:10.3390/biology12091202
What was done
This narrative review traces the development history of rapamycin (sirolimus), from its 1964 discovery in Easter Island soil as an antifungal and immunosuppressive agent to its modern application in hemoglobinopathies. It describes preclinical in vitro work on primary erythroid precursor cells from beta-thalassemia patients, in vivo animal studies, and the rationale for human clinical trials evaluating rapamycin as an inducer of gamma-globin gene expression and fetal hemoglobin (HbF).
What was found
The abstract reports no quantitative values or statistical effect sizes. It summarizes qualitatively that rapamycin stimulates gamma-globin expression and increases HbF production in isolated patient erythroid precursor cells, in experimental mouse models, and in treated patients.
Why it matters
Elevating fetal hemoglobin is a validated therapeutic strategy in beta-thalassemia, and summarizing the translational pipeline for sirolimus highlights its potential utility as an oral disease-modifying agent.
Limits
The abstract contains no primary data, quantitative outcomes, or details on sample sizes and trial phases. Because this is a narrative review, it does not apply systematic review methodology or risk-of-bias evaluation to the underlying studies.
Cited by
- supports Sirolimus (rapamycin) is a naturally occurring compound discovered in a soil sample from Easter Island (Rapa Nui).